NHS Approves First Major Stomach Cancer Drug in a Decade

For thousands facing stomach cancer each year, a new treatment offers something precious: more time with the people they love.

The UK's National Health Service just approved durvalumab, an immunotherapy drug that helps the body's immune system fight aggressive stomach cancer. About 1,500 people annually will now have access to this treatment through the NHS, marking the first major breakthrough in stomach cancer care in nearly a decade.

The drug works alongside chemotherapy for adults whose stomach cancer hasn't spread extensively and can be surgically removed. Clinical trials showed it significantly increases the time before cancer progresses and improves overall survival rates.

Helen Knight, director of medicines evaluation at the National Institute for Health and Care Excellence, called stomach cancer a devastating disease with high recurrence rates after surgery. She emphasized the urgent need for treatments that extend both length and quality of life.

Stomach cancer, also called gastric cancer, occurs when abnormal cells in the stomach grow uncontrollably. Around 6,800 people receive this diagnosis in the UK each year, making it the 18th most common cancer nationwide.

The disease carries a heavy burden. Patients endure major surgery while living with constant fear that cancer will return. High recurrence rates have meant families often faced heartbreak even after initial treatment success.

The Ripple Effect

This approval represents more than a new drug on pharmacy shelves. It offers renewed hope to families who've watched loved ones battle a particularly aggressive cancer with limited treatment options.

Sheena Dewan, executive director at Stomach Cancer UK, described the dual burden patients have carried for too long. Adding immunotherapy to existing chemotherapy gives people a meaningful opportunity for more time at work, with loved ones, and living well beyond treatment.

The treatment targets a critical gap in care. While surgery removes visible cancer, microscopic cells often remain, leading to devastating recurrence. Immunotherapy helps the body hunt down these remaining cells, giving patients a better chance at long-term survival.

For families who've spent years hoping for advancement, this decision brings tangible progress. More time means more birthdays celebrated, more ordinary moments treasured, and more memories made together.

After nearly a decade without major treatment advances, stomach cancer patients finally have reason for renewed optimism.